Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$3.11
▲ $0.03 (+1.0%)
Market data updated: 09/20 03:38 AM
Fundamentals updated: 09/20/2026
News analyzed: 09/20/2026
Market Cap
$222.90M
Day Range
$2.99 - $3.18
52-Week Range
$1.21 - $6.95
Beta
—
Next Earnings
09.11.2026
Support
$2.99
Resistance
$5.58
ZNTL is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+108.7% (1Y)
Strengths: 5/24 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🔴 Bearish
Technical Trend
🔴 Bearish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Free cash flow growth
Free cash flow growth: 26.8%
Growth
Biggest negative driver
DCF Fair Value
Estimated fair value: -$23.02 vs. price $3.11 (-840.3%)
Fair Value
Signal tension
Growth scores strong (62/100), but fair-value analysis scores this stock as relatively expensive (38/100) — the growth story and the current price aren't fully aligned.
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
40
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
62
Quality
No data available
Value
38
Momentum
13
Risk
40
Sentiment
62
Fundamental
46
Institutional
6
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Zentalis Pharmaceuticals, Inc. has focused on its ongoing clinical development of **azenosertib**, a first-in-class WEE1 inhibitor for ovarian cancer, particularly its biomarker-driven treatment approach. Key themes include the company’s participation in investor conferences, recent stock grants under Nasdaq listing rules, and a $93 million funding raise to extend its pipeline. Analysts await mid-2027 data to assess azenosertib’s potential, while insider buying and a completed share offering highlight investor confidence.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Zentalis Pharmaceuticals, Inc.. News trend score: 62. Reason: 6 of the last 20 articles are positive, versus 4 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
34
🎯 Conviction (vs. Emotion)
36
Psychology
41
Fundamentals
46
Technical
13
Valuation
38
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
A significant decline over time, but on unusually low trading volume — holders unwilling to accept the loss.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price (3M)
-16%
Market Narrative
37
Fundamental Reality
36
Narrative Gap
+1
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market behavior for ZNTL suggests a dominant **confirmation bias**, where investors prioritize narrative-driven optimism (+52 narrative score) over deteriorating fundamentals (revenue down -1.0%). Overconfidence (score 12) aligns with price momentum outpacing EPS growth, while FOMO (15) hints at cautious momentum chasing. The absence of panic or herding implies a selective, narrative-focused approach. The key open question: will fundamentals eventually override the narrative gap, or will investors sustain this disconnect?
Updated: 09/09/2026, 08:53 AM
What could change this?
👥 What the crowd believes
"members of the management team will participate in the following upcoming investor conferences"
"granted non-qualified stock options to purchase an aggregate of 269,000 shares"
"Zentalis Pharmaceuticals Closes Offering of Common Shares"
"1H27 data catalyst"
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Walter Bagehot — 100/100
🔴 Weakest match
Edgar Lawrence Smith — 8/100
🗣️ Why do they disagree?
The stark divide in verdicts for ZNTL reflects deep methodological disagreements about risk, growth, and market timing. Bagehot, Mackay, and Graham’s defensive approach all score near-perfectly, seeing it as a resilient, low-mania opportunity with strong fundamentals—likely because it meets their criteria for liquidity, stability, and undervaluation. In contrast, Fisher, Lynch, and Livermore dismiss it outright, with Fisher and Lynch rejecting its growth profile and Livermore flagging a negative trend, while Malkiel/Bogle and Nelson view it as overpriced or cyclically stretched. Marks’ nuanced cycle analysis splits the difference, acknowledging early-cycle potential but not deep value, while Loeb and Smith’s high-risk aversion and long-term stability demands lead them to outright reject it. The middle ground—Schwager’s indecision, Housel’s cautious hold, and Veblen’s profit ambiguity—shows where even pragmatic investors struggle to reconcile growth signals with profitability.
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟢 99
Attractive to a Defensive Graham Investor
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 35%
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 99
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 95
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 81
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟢 80
Deep statistical discount — a real Enterprising Investor candidate
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟢 68
A real, disciplined setup with favorable reward/risk
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 64
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 51
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 45
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
⚠️ Partial data for this stock — score is less reliable — Data availability: 40%
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟡 45
Moderate — holdable, but not effortless
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 39
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟡 38
Doesn't clear Lynch's growth-at-a-reasonable-price bar
Key question
Is the growth worth the price?
⚠️ Partial data for this stock — score is less reliable — Data availability: 40%
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 36
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 18
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 8
Doesn't show the stability Smith's long-term case requires
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (0 bullish · 10 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
High confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
—
Net Margin
—
EBITDA Margin
—
ROE
-63.4%
ROA
-47.4%
ROIC
—
EPS
-$1.91
Cash
$35.99M
Total Debt
—
Current Ratio
6.93
Debt/Equity
—
How is Fair Value calculated? →
Current Price
$3.11
Estimated Fair Value (DCF)
-$23.02
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-840.3%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
-5.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | -5.0% | $-118.98M | $-109.16M |
| 2 | -3.1% | $-115.27M | $-97.02M |
| 3 | -1.2% | $-113.83M | $-87.89M |
| 4 | 0.6% | $-114.54M | $-81.14M |
| 5 | 2.5% | $-117.40M | $-76.30M |
Base FCF (last actual year)
$-125.25M
Terminal Value
$-1.85B
Present Value of Terminal Value
$-1.20B
Enterprise Value
$-1.65B
Net Debt
$0
Equity Value
$-1.65B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$3.01
Tangible Book Value per Share (Tangible NAV)
$3.01
Sentiment based on basic keywords (not AI) — 6 positive, 10 neutral, 4 negative out of the last 20 articles.
Benzinga · 16.9.2026
Benzinga · 16.9.2026
SeekingAlpha · 14.9.2026
Yahoo · 2.9.2026
GlobeNewswire · 2.9.2026
Yahoo · 1.9.2026
GlobeNewswire · 1.9.2026
SeekingAlpha · 31.8.2026
MT Newswires · 20.8.2026
Benzinga · 20.8.2026
MT Newswires · 17.8.2026
GlobeNewswire · 17.8.2026
MT Newswires · 14.8.2026
MT Newswires · 14.8.2026
MT Newswires · 14.8.2026
Benzinga · 14.8.2026
MT Newswires · 14.8.2026
GlobeNewswire · 14.8.2026
GlobeNewswire · 13.8.2026
Benzinga · 13.8.2026
Zentalis Pharmaceuticals, Inc. (ZNTL) currently has a StockIQ AI score of 40/100, rated "Weak" (a partial score — based on only 6 of 7 categories, some data is currently unavailable). The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
ZNTL currently scores 40/100 (Weak) across the categories we measure (a partial score — based on only 6 of 7 categories, some data is currently unavailable). StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, ZNTL's estimated fair value is -$23.02, which is 840.3% below the current price of $3.11. This is one valuation model among several signals in the fair-value category, not a price target.
ZNTL's technical score is 13/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Free cash flow growth: 26.8%; Current ratio: 6.93; Earnings per share (EPS) growth: 18.0%.
Based on the real signals StockIQ computed: Estimated fair value: -$23.02 vs. price $3.11 (-840.3%); ATR: 8.0% of price; Calmar: -0.50 (3y annualized return -48.1% / max drawdown 95.4%).
StockIQ has no recorded dividend payment history for ZNTL.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 1 purchases and 16 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| WALTERS GROUP | Open Market Purchase | 14.8.2026 | 4,335,000 | +4,335,000 | $3.50 |
| Myers Scott Dunseth | Grant/Award from Employer | 16.6.2026 | 57,100 | +57,100 | — |
| Johnson David Michael | Grant/Award from Employer | 16.6.2026 | 57,100 | +57,100 | — |
| Kariuki Enoch | Grant/Award from Employer | 16.6.2026 | 57,100 | +57,100 | — |
| Skvarka Jan | Grant/Award from Employer | 16.6.2026 | 57,100 | +57,100 | — |
| Walker Luke Nathaniel | Grant/Award from Employer | 16.6.2026 | 57,100 | +57,100 | — |
| Myers Scott Dunseth | Grant/Award from Employer | 16.6.2026 | 395,895 | +57,100 | — |
| Campbell Shannon | Grant/Award from Employer | 26.5.2026 | 114,200 | +114,200 | — |
| Campbell Shannon | Grant/Award from Employer | 26.5.2026 | 114,200 | +114,200 | — |
| Vultaggio Vincent | Open Market Sale | 10.2.2026 | 6,894 | -6,894 | $2.42 |
| Vultaggio Vincent | Open Market Sale | 10.2.2026 | 146,506 | -6,894 | $2.42 |
| EASTLAND JULIA MARIE | Open Market Sale | 9.2.2026 | 889 | -889 | $2.39 |
| Vultaggio Vincent | Open Market Sale | 9.2.2026 | 3,379 | -3,379 | $2.39 |
| Bruns Ingmar | Open Market Sale | 9.2.2026 | 335 | -335 | $2.39 |
| EASTLAND JULIA MARIE | Open Market Sale | 9.2.2026 | 79,133 | -889 | $2.39 |
| Bruns Ingmar | Open Market Sale | 9.2.2026 | 33,332 | -335 | $2.39 |
| Vultaggio Vincent | Open Market Sale | 9.2.2026 | 153,400 | -3,379 | $2.39 |
| Bruns Ingmar | Open Market Sale | 6.2.2026 | 2,962 | -2,962 | $2.43 |
| EASTLAND JULIA MARIE | Open Market Sale | 6.2.2026 | 7,866 | -7,866 | $2.43 |
| Vultaggio Vincent | Open Market Sale | 6.2.2026 | 29,951 | -29,951 | $2.43 |
| EASTLAND JULIA MARIE | Open Market Sale | 6.2.2026 | 80,022 | -7,866 | $2.43 |
| Bruns Ingmar | Open Market Sale | 6.2.2026 | 33,667 | -2,962 | $2.43 |
| Vultaggio Vincent | Open Market Sale | 6.2.2026 | 156,779 | -29,951 | $2.43 |
| Vultaggio Vincent | Open Market Sale | 3.2.2026 | 556 | -556 | $2.52 |
| Vultaggio Vincent | Open Market Sale | 3.2.2026 | 186,730 | -556 | $2.52 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
4,989,106 shares short as of 2026-08-31 · vs. 5,578,646 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
65.0% of trading volume this week was short selling, vs. 67.5% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology